Abstract:To improve arrhythmogenic cardiomyopathy (ACM) patient care four pillars of ACM research are necessary. The first pillar to improve ACM is cohort studies in which the genotype‐specific natural history of disease is described, and subsequently genotype‐specific risk calculators can be developed, such as the DSP and PLN risk calculators. The second pillar is the basic and translational studies in which cellular pathways are described and potential genotype‐specific drug targets to slow progression or lower the risk of VA identified, such as flecainide in PKP2‐associated ARVC patients. Third, preclinical gene studies can improve ACM patient care to determine which vector has the optimal effect in which specific gene for gene therapy. The efficacy of gene therapy can subsequently be tested to hopefully improve or even cure ACM in clinical trials. Arrhythmogenic cardiomyopathy (ACM) is a genetically heterogeneous inherited cardiomyopathy with an estimated prevalence of 1:5000–10 000 that predisposes patients to life‐threatening ventricular arrhythmias (VA) and sudden cardiac death (SCD). ACM diagnostic criteria and risk prediction models, particularly for arrhythmogenic right ventricular cardiomyopathy (ARVC), the most common form of ACM, are typically genotype‐agnostic, but numerous studies have established clinically meaningful genotype‐phenotype associations. Early signs of ACM onset differ by genotype indicating the need for genotype‐specific diagnostic criteria and family screening paradigms. Likewise, risk factors for SCD vary by genetic subtype, indicating that genotype‐specific guidelines for management are also warranted. Of particular importance, genotype‐specific therapeutic approaches are being developed. Results from a randomized controlled trial for flecainide use in ARVC patients are currently pending. Research in a plakophilin‐2‐deficient mouse model suggests this antiarrhythmic drug may be particularly useful for patients with likely pathogenic or pathogenic (LP/P) PKP2 variants. Additionally, the first gene therapy clinical trials in ARVC patients harboring LP/P PKP2 variants are currently underway. This review aims to provide clinicians caring for ACM patients with an up‐to‐date overview of the current literature in genotype‐specific natural history of disease and management of ACM patients and describe scientific advances that have led to upcoming clinical trials.

Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)

Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence‐based practice resource of the National Society of Genetic Counselors

Genetic Testing in Hypertrophic Cardiomyopathy

Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity

Role of Genetics in Diagnosis and Management of Hypertrophic Cardiomyopathy: A Glimpse into the Future

Genetics of dilated cardiomyopathy: practical implications for heart failure management

An Evidence-based Assessment of Genes in Dilated Cardiomyopathy

Emerging Themes in Genetics of Hypertrophic Cardiomyopathy. Current status and clinical application.

Clinical Genetic and Genomic Testing in Congenital Heart Disease and Cardiomyopathy

[Clinical Practice Guidelines for Hereditary Non-Syndromic Deafness].

Reinterpretation of genetic testing for Cardiomyopathies: Less is more

Hereditary Hypertrophic Cardiomyopathy in Children and Young Adults—The Value of Reevaluating and Expanding Gene Panel Analyses

Considering complexity in the genetic evaluation of dilated cardiomyopathy

Correspondence on ACMG STATEMENT: ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG) by Miller et al

ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel: Reappraisal of Genes associated with Hypertrophic Cardiomyopathy

Contemporary review on pediatric hypertrophic cardiomyopathy: insights into detection and management

A Genetic Journey from Past to Future

Gene therapy in cardiology: is a cure for hypertrophic cardiomyopathy on the horizon?

Arrhythmogenic Cardiomyopathy: Towards Genotype Based Diagnoses and Management

Unveiling the Spectrum of Minor Genes in Cardiomyopathies: A Narrative Review

Prevalence of Genetically Associated Dilated Cardiomyopathy: A Systematic Literature Review and Meta-Analysis